These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature. Usui J; Glezerman IG; Salvatore SP; Chandran CB; Flombaum CD; Seshan SV Hum Pathol; 2014 Sep; 45(9):1918-27. PubMed ID: 25087655 [TBL] [Abstract][Full Text] [Related]
5. Toxicity of concurrent stereotactic radiotherapy and targeted therapy or immunotherapy: A systematic review. Kroeze SG; Fritz C; Hoyer M; Lo SS; Ricardi U; Sahgal A; Stahel R; Stupp R; Guckenberger M Cancer Treat Rev; 2017 Feb; 53():25-37. PubMed ID: 28056412 [TBL] [Abstract][Full Text] [Related]
6. Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy. Hsu JY; Wakelee HA BioDrugs; 2009; 23(5):289-304. PubMed ID: 19754219 [TBL] [Abstract][Full Text] [Related]
7. Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies. Grothey A; Ellis LM Cancer J; 2008; 14(3):170-7. PubMed ID: 18536556 [TBL] [Abstract][Full Text] [Related]
8. Angiogenesis inhibition in the treatment of lung cancer. Vokes E; Herbst R; Sandler A Clin Adv Hematol Oncol; 2006 Nov; 4(11 Suppl 23):1-10; quiz 11-2. PubMed ID: 17143257 [TBL] [Abstract][Full Text] [Related]
9. Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab in combination with sorafenib in patients with advanced malignant melanoma. Mahalingam D; Malik L; Beeram M; Rodon J; Sankhala K; Mita A; Benjamin D; Ketchum N; Michalek J; Tolcher A; Wright J; Sarantopoulos J Cancer Chemother Pharmacol; 2014 Jul; 74(1):77-84. PubMed ID: 24817603 [TBL] [Abstract][Full Text] [Related]
11. [Combination of stereotactic irradiation and chemotherapy or targeted therapies: state of the art and preliminary recommendations]. Thariat J; Kirova Y; Milano G; Mornex F Cancer Radiother; 2014; 18(4):270-9. PubMed ID: 25053603 [TBL] [Abstract][Full Text] [Related]
12. Angiogenesis inhibition with bevacizumab and the surgical management of colorectal cancer. Thornton AD; Ravn P; Winslet M; Chester K Br J Surg; 2006 Dec; 93(12):1456-63. PubMed ID: 17115389 [TBL] [Abstract][Full Text] [Related]
13. Phase 1 Trial of Sorafenib and Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma. Brade AM; Ng S; Brierley J; Kim J; Dinniwell R; Ringash J; Wong RR; Cho C; Knox J; Dawson LA Int J Radiat Oncol Biol Phys; 2016 Mar; 94(3):580-7. PubMed ID: 26867886 [TBL] [Abstract][Full Text] [Related]
14. Drug insight: antiangiogenic therapies for gastrointestinal cancers--focus on monoclonal antibodies. Reinacher-Schick A; Pohl M; Schmiegel W Nat Clin Pract Gastroenterol Hepatol; 2008 May; 5(5):250-67. PubMed ID: 18382435 [TBL] [Abstract][Full Text] [Related]
15. Bevacizumab in the treatment of breast cancer. Koutras AK; Fountzilas G; Makatsoris T; Peroukides S; Kalofonos HP Cancer Treat Rev; 2010 Feb; 36(1):75-82. PubMed ID: 19932567 [TBL] [Abstract][Full Text] [Related]
16. Treatment of steroid refractory, Gamma Knife related radiation necrosis with bevacizumab: case report and review of the literature. Sanborn MR; Danish SF; Rosenfeld MR; O'Rourke D; Lee JY Clin Neurol Neurosurg; 2011 Nov; 113(9):798-802. PubMed ID: 21906869 [No Abstract] [Full Text] [Related]
17. Duodenal and other gastrointestinal toxicity in cervical and endometrial cancer treated with extended-field intensity modulated radiation therapy to paraaortic lymph nodes. Poorvu PD; Sadow CA; Townamchai K; Damato AL; Viswanathan AN Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1262-8. PubMed ID: 23182395 [TBL] [Abstract][Full Text] [Related]
18. Antiangiogenesis beyond VEGF inhibition: a journey from antiangiogenic single-target to broad-spectrum agents. Limaverde-Sousa G; Sternberg C; Ferreira CG Cancer Treat Rev; 2014 May; 40(4):548-57. PubMed ID: 24360358 [TBL] [Abstract][Full Text] [Related]
19. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Shih T; Lindley C Clin Ther; 2006 Nov; 28(11):1779-802. PubMed ID: 17212999 [TBL] [Abstract][Full Text] [Related]